Aerocrine signs UK & Irish partnership deal with Healthcare

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 17, 2014 at 2:15 AM

Aerocrine signs UK & Irish partnership deal with Healthcare 21.

Solna (Sweden) – January 17, 2014 – Aerocrine AB (OMX Nordic Exchange: AERO) today announces the signing of an exclusive agreement with UK & Irish medical device company Healthcare 21 Ltd for sales, marketing and distribution of Aerocrine’s new airway inflammation monitor and test kit – NIOX VERO® – across the UK and Ireland. The agreement goes into effect on February 1, 2014 and gives Healthcare 21 exclusive rights for the sales marketing and distribution of Aerocrine’s new instrument NIOX VERO® and test kits, used for diagnosing and monitoring patients with asthma. The agreement also includes Healthcare 21 taking on the support, sales and distribution for the already installed base of Aerocrine’s NIOX MINO® devices across the UK & Irish market. “As we continue the roll out of our new product, NIOX VERO® in the UK and Ireland, we are delighted to be partnering with Healthcare 21, who is a leading sales and marketing distributor with an existing and substantial UK & Irish operation and proven track record of success in the respiratory and secondary care market. This deal is part of Aerocrine’s strategy of substantially growing the European business in a cost-efficient manner,” says David Plotts, Aerocrine VP of International Sales & UK General Manager. Aerocrine is committed to maintaining a substantial profile and direct presence in the UK and Irish market to support development of FeNO guidelines, KOL management, engagement with payers with particular focus and attention on the primary care sector. Aerocrine will also directly continue to focus on developing opportunities as a result of forthcoming NICE Guidance on FeNO and in new healthcare environments such as pharmacy and occupational health. Aerocrine offers versatile and easy-to-use monitoring devices for fractional exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for research and clinical applications are used for routine measurements in both specialist and primary care clinics, and can be used to improve the management of allergic airway inflammation, such as asthma. “We are delighted to partner with Aerocrine in the UK and Ireland and we look forward to supporting both existing and future customers whilst also working with Aerocrine to establish FeNO testing as the standard of care method for measuring allergic airway inflammation in our marketplaces” says David Frederick, MD of Healthcare21 NIOX VERO® and NIOX MINO® offer added advantages for patient care, including detecting allergic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy. For more information, contact: Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368 0336 David Plotts, Vice President International Sales, Aerocrine Ltd, +44 7891 433239 David Frederick, Managing Director, Healthcare 21 +44 7585 552655 About Healthcare 21 The Healthcare 21 Group is a leading privately owned medtech sales and marketing group of companies with an existing and substantial infrastructure in the UK & Ireland. HC21 works in diversified fields and has long term distribution agreements with leading multinational organizations. About Aerocrine Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow -up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on January 17, 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Independents Finally Center Stage on Election Night

Unprecedented Spotlight on Independent Voters The political landscape is in for a shake-up, folks. Come November 3rd, we're witnessing something that hasn't been done before—an entire Election Night dedicated exclusively to independent voters. It’s high time these folks got the spotlight, considering a whopping 45% of U.S. adults have shunned the extremist seesaw of...

Pacsun Finds Gear: 177% Sales Surge at F1 Austin!

New Heights in Trackside Fashion Well, it looks like Pacsun's got a knack for making the Austin F1 scene as thrilling as the race itself, weaving fashion into the high-speed atmosphere. This year's Formula 1 United States Grand Prix in Austin brought a whopping 19% sales swell in 2026, marking a total sales increase of 177% since their initial 2023 Austin pop-up. Talk...

EQS Group's Climate Goals Get SBTi Validation

EQS Group's Bold Climate Commitments The news hits like a gust of clean air — EQS Group's climate targets are now stamped with the seal of approval from the Science Based Targets initiative (SBTi). This isn't just your typical corporate green pledge: we're talking serious, validated commitments pushing for net-zero emissions by 2050. Decoding EQS Group's Impactful...

Surgery Partners Buyout: Fair Deal or Insider Jackpot?

What's Going On With Surgery Partners? Alright, here's the scoop that shareholders can't ignore—Surgery Partners (NYSE:SGRY) could be heading under the scalpel itself with a proposed buyout by HealthSpan. For those holding onto SGRY stock, this might feel like watching the rerun of a medical drama where the ending ain't clear yet. Shareholders are set to get $23.50 a...

Aktonomy 2026: Tackling New AI Security Frontiers

Cracking Open the AI Security Code Today's tech landscape feels like a high-stakes game of chess. Akto's Aktonomy Fall '26, scheduled for October 27, 2026, is set to put the biggest AI security challenges under the microscope. In the world of security, there's no room for dithering, and Akto knows it. This event aims to dive deep into the concepts that enterprise security...

Ademi LLP Questions RRC Buyout Deal's Fairness

Unease Surrounds RRC's Potential Acquisition by EQT Let’s talk about a messy situation brewing with Range Resources Corporation (NYSE: RRC). The lawyers at Ademi LLP are poking around in the shadows of a proposed buyout by EQT Corporation, questioning whether the deal is legit—or if someone’s getting the short end of the stick. It’s all happening in a climate...

Post University Expands with New Tech and Health Degrees

If you're looking to invest in an education with promising payoffs, you might look into what's cooking over at Post University. They've just dropped a bombshell of new programs sure to get some attention from tech heads and health nuts alike, and I can't help but think there's potential brewing here. New Academic Paths Emerge Post University isn't resting on its...

FOX's Watters Hosts Town Hall with VP Vance

By Hannah Lewis Updated Oct 26, 2026 Category News Views 136

What's Brewing Between Jesse Watters and JD Vance? Who would've thought Texas would be the stage for FOX's Jesse Watters and Vice President JD Vance to lock horns over the country's pressing issues? Set your sights on the Lone Star State this October 29th as Watters rolls out the red carpet for Vance during Jesse Watters Primetime. It's a pre-taped town hall meet-up,...

San Ysidro Urgent Care Addresses Care Desert in San Diego

A Long Overdue Remedy in San Diego Healthcare access shouldn't be a roll of the dice based on where you live, but for too many folks in Southeastern San Diego, that’s been the sad reality. Today, though, there's a new twist in the tale. Blue Shield of California Promise Health Plan just dropped a hefty $1 million into an urgent care facility that’s more than bricks...

Exploring Family, Faith, and Forgiveness in New Book

Diving into the Depths of Faith and Forgiveness T.L. Dennis ain't just spinning a yarn about his childhood in "A Conversation with a Dead Father". This is a deep dive into the gritty realities of his relationship with his old man, seasoned with the salt of personal struggles and spiritual redemption. The pages of this book open at the one place none of us look for good...